Cognito Therapeutics

💭 Cognitive Health· 📍 Cambridge, MA, USA

Overview

Cognito Therapeutics is developing non-invasive sensory stimulation therapies using 40Hz gamma frequency light and sound to target the neurological mechanisms underlying Alzheimer's disease. Their OVERTURE Phase 3 clinical trial is evaluating the Cognito Therapy System for slowing cognitive and functional decline in mild-to-moderate Alzheimer's patients.

More in Cognitive Health

Neural Leap

Toronto, Ontario, Canada

NeuralMind Health

London, United Kingdom

Mnemo Health

London, UK

Myelin Health

Boston, MA

Axon Park

Toronto, Ontario, Canada

Cortical.io

Vienna, Austria

Latest industry news

Precision Neuroscience Raises $250M to Accelerate Brain-Computer Interface Development

2026-11-01 · Funding

Merge Labs Gets Competition as New Rival Neurotech Startup Enters the Consumer BCI Arena

2026-10-31 · Industry

Neuralink Connects to Grok AI Agent, Enabling ALS Patient to Control AI and Make Calls by Thought Alone

2026-10-30 · Product

Implanted BCIs Still Lack a Shared Safety Rulebook, and the Field Is Running Out of Time to Write One

2026-10-29 · Research

Company details

Is this your company?

Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.

Claim & upgrade listing

Advertise

Reach neurotech professionals

Newsletter sponsorships, featured listings, and sponsored articles.

View packages →